Abstract
This retrospective study investigated the clinicopathological characteristics of secretory carcinoma of salivary glands (SCSG) in 23 patients with histopathologically confirmed SCSG between January 2010 and December 2020. In total, 13 males and 10 females (ratio, 1.3:1) aged 10 − 69 years (median, 45 years) were enrolled in this study; the average disease duration was 2.44 years (0.25–20 years). Twenty-one patients (91.3%) had SCSG in the parotid gland, and two (8.7%) in the submandibular gland. All patients had single nodules of diameters 0.8–4.8 cm (average 2.6 cm); five with lymph node metastases, and two with distant metastases. Immunohistochemically, tumors stained positive for S-100, mammaglobin, CK7, GATA3 and pan-Trk, and negative for DOG1, P63, and calponin, with Ki-67 positivity from 1 to 50%. ETV6 gene rearrangement was confirmed in 15 patients. All patients underwent oncological resection, four had radioactive particles implanted postoperatively, one received chemotherapy, and seven underwent chemoradiotherapy. Six patients had regional recurrences, two distant metastases, and one died before the last follow-up. SCSGs are typically indolent, with a low locoregional recurrence rate and excellent survival. Prognosis is correlated to clinical stage, pathological grade, and surgical procedures.
Highlights
This retrospective study investigated the clinicopathological characteristics of secretory carcinoma of salivary glands (SCSG) in 23 patients with histopathologically confirmed SCSG between January 2010 and December 2020
The updated World Health Organization (WHO) Classification for Head and Neck Tumors (4th edition, 2017) substituted mammary analog secretory carcinoma with secretory c arcinoma[3]. These salivary gland tumors are characterized by the presence of a t(12;15)(p13;q25) translocation, which leads to the fusion of the translocation-Ets-leukemia virus (ETV6) gene on chromosome 12, and the neurotrophic tropomyosin receptor kinase 3 (NTRK3) gene on chromosome 1 54
We present a review of 23 patients with SCSG in major salivary glands who were treated in our department at the First Affiliated Hospital of Zhengzhou University, including a detailed discussion of clinicopathological characteristics, outcomes of treatment, and prognosis
Summary
This retrospective study investigated the clinicopathological characteristics of secretory carcinoma of salivary glands (SCSG) in 23 patients with histopathologically confirmed SCSG between January 2010 and December 2020. Diagnostic criteria for secretory carcinoma of salivary glands (SCSG), a recently described rare malignant tumor, were first introduced by Skálová et al.[1]. The updated World Health Organization (WHO) Classification for Head and Neck Tumors (4th edition, 2017) substituted mammary analog secretory carcinoma with secretory c arcinoma[3]. These salivary gland tumors are characterized by the presence of a t(12;15)(p13;q25) translocation, which leads to the fusion of the translocation-Ets-leukemia virus (ETV6) gene on chromosome 12, and the neurotrophic tropomyosin receptor kinase 3 (NTRK3) gene on chromosome 1 54.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
